Selective Alpha 4 Beta 7 Integrin Small Molecules for Oral Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current α4ß7 integrin inhibitors, such as ENTYVIO, require parenteral administration and cause significant side effects due to their long half-life, necessitating the development of orally available and highly selective α4ß7 small molecule inhibitors with reduced side effects.
Innovation Solution
Development of compounds with specific structural features that selectively target α4ß7 integrin, offering over 100-fold or 1,000-fold selectivity over α4ß1, designed to mimic the anti-inflammatory effects of ENTYVIO, allowing for oral bioavailability and reduced off-target binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ENTYVIO (vedolizumab) is used to target α4ß7 integrin, then anti-inflammatory efficacy is achieved, but parenteral administration is required and side effects occur due to long half-life
Solution Approach 1:
The patent replaces the monoclonal antibody mechanism (ENTYVIO) with small molecule inhibitors that bind to α4ß7 integrin. These small molecules achieve similar anti-inflammatory efficacy through oral administration, eliminating the need for parenteral injection and improving patient convenience while maintaining therapeutic effectiveness
Solution Approach 2:
The patent modifies the pharmacokinetic parameters by developing small molecule inhibitors with shorter half-lives compared to ENTYVIO. This allows for more flexible dosing intervals and reduced accumulation of side effects, while maintaining sufficient α4ß7 integrin blocking activity for therapeutic efficacy
2Reliability
If ENTYVIO is used to target α4ß7 integrin, then anti-inflammatory efficacy is achieved, but significant side effects occur due to long half-life
Solution Approach 1:
The patent employs small molecule inhibitors with shorter half-lives that can be rapidly cleared from the body after serving their therapeutic function. This short-lived approach allows for quicker cessation of side effects compared to ENTYVIO's long half-life, reducing the burden of adverse events while maintaining effective α4ß7 integrin blockade during treatment
Solution Approach 2:
The patent changes the pharmacokinetic parameter of half-life from ENTYVIO's long duration to shorter durations for the small molecule inhibitors. This parameter change enables faster elimination of the drug and its metabolites, thereby reducing the duration and severity of side effects while preserving therapeutic efficacy through optimized dosing regimens
3Ease of operation
If small molecule inhibitors are developed to replace ENTYVIO, then oral bioavailability is achieved, but selectivity over α4ß1 must be maintained to reduce off-target binding
Solution Approach 1:
The patent employs structure-activity relationship (SAR) analysis to optimize the local chemical features of the small molecule inhibitors. By carefully selecting and positioning specific functional groups and molecular moieties, the compounds achieve high affinity binding to α4ß7 integrin while minimizing interaction with α4ß1, thus achieving both oral bioavailability and selective activity
Solution Approach 2:
The patent optimizes binding affinity parameters and selectivity ratios through iterative structure optimization. The small molecule inhibitors are designed with specific molecular weights, hydrophobicity levels, and functional group configurations that enable oral absorption while maintaining over 100-fold selectivity for α4ß7 over α4ß1, preventing off-target effects
Data Source
AI summary
The present disclosure provides small molecule compounds and pharmaceutical compositions for the modulation of alpha 4 beta 7 integrin, useful for the treatment of inflammatory conditions such as inflammatory bowel disease, including ulcerative colitis and Crohn's disease.